Back
Market Access Mindset

๐‚๐ก๐š๐ง๐ง๐ž๐ฅ ๐’๐ญ๐ซ๐š๐ญ๐ž๐ ๐ฒ ๐ˆ๐ฌ ๐–๐ก๐ž๐ซ๐ž ๐€๐œ๐œ๐ž๐ฌ๐ฌ ๐Œ๐ž๐ž๐ญ๐ฌ ๐„๐ฑ๐ž๐œ๐ฎ๐ญ๐ข๐จ๐ง

As we conclude our PCC series after exploring Pricing as the strategic lever and Contracting as the bridge, itโ€™s time to examine Channel strategy. These decisions are where PCC plans are put into practice, and mistakes here can unravel an entire strategy. Channel strategy isnโ€™t just logistics, itโ€™s how your therapy moves from concept to delivering on your commitment to patient access, commercial efficiency, and strategic differentiation.

Several unique contributors, including your warehouse, 3PL, specialty distributors, wholesalers, pharmacies, couriers, GPOs, clinics and physicians comprise the channel and they need to be linked efficiently to optimize your commercial success and ease the patient journey.ย Carefully selecting and aligning partners based on a medicine attributes, capabilities and requirements is complex. Here are some of the key considerations:

๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š ๐š๐ง๐ ๐Œ๐ž๐๐ข๐œ๐ข๐ง๐ž ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ž๐ฑ๐ข๐ญ๐ฒ

–ย Specialty medicines often require limited distribution models due to site of care, handling, administration and/or reimbursement complexities while other medicines with a limited time window to treat, retail access and less handling complexity may require broader models
–ย Cold-chain medicines require specialized capabilities to maintain integrity
–ย Controlled substances or REMs must comply with FDA and/or global regulations.

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐๐ž๐ž๐๐ฌ ๐€๐ฌ๐ฌ๐ž๐ฌ๐ฌ๐ฆ๐ž๐ง๐ญ

–ย Understand the demographics & distribution of patients. Rural markets may rely on home delivery, while more urban markets may prioritize retail or acute sites of care
– Consider provider acquisition preferences, economics and GPO relationships
–ย Evaluate Payer/PBM policies that may steer patients to preferred channels
–ย Analyze competitorsโ€™ channel strategies to identify gaps and/or opportunities

๐‚๐ก๐š๐ง๐ง๐ž๐ฅ ๐„๐Ÿ๐Ÿ๐ข๐œ๐ข๐ž๐ง๐œ๐ฒ, ๐…๐ž๐ž ๐’๐ญ๐ซ๐ฎ๐œ๐ญ๐ฎ๐ซ๐ž๐ฌ ๐š๐ง๐ ๐‘๐ž๐ฏ๐ž๐ง๐ฎ๐ž ๐ˆ๐ฆ๐ฉ๐š๐œ๐ญ

–ย Evaluate each channel cost against net revenue to optimize access & profitability
– Carefully model bona fide service fee and price concession structures for accurate grossโ€‘toโ€‘net forecasts, ASP modeling and government price reporting
– Ensure flexibility to adapt to market changes, such as shifts in demand, new regulations, and/or line extensions

๐‚๐ก๐š๐ง๐ง๐ž๐ฅ ๐ฆ๐ข๐ฌ๐š๐ฅ๐ข๐ ๐ง๐ฆ๐ž๐ง๐ญ ๐œ๐š๐ง ๐ซ๐ž๐ฌ๐ฎ๐ฅ๐ญ ๐ข๐ง:
–ย Suboptimal net revenue & margin erosion
–ย Access bottlenecks
–ย Compliance missteps in price reporting and/or contract deliverables
–ย Disconnects between strategy and execution

๐…๐ข๐ง๐š๐ฅ ๐“๐š๐ค๐ž๐š๐ฐ๐š๐ฒ: When thoughtfully integrated, your Channel strategy can provide competitive advantage, ensure compliance and enhance patient access. Execute with intention so that your therapy is poised to reach its maximum potential.ย Contact us at info@A3Access.com for help with your PCC strategy.